Aspira Pathlab Intrinsic Value
ASPIRA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹31.68 | ₹25.34 - ₹38.02 | -49.3% | EPS: ₹2.64, Sector P/E: 12x |
| Book Value Method | asset | ₹12.50 | ₹11.25 - ₹13.75 | -80.0% | Book Value/Share: ₹12.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹19.20 | ₹17.28 - ₹21.12 | -69.3% | Revenue/Share: ₹24.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹25.01 | ₹22.51 - ₹27.51 | -60.0% | EBITDA: ₹4.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹27.17 | ₹21.74 - ₹32.60 | -56.5% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹18.76 | ₹16.88 - ₹20.64 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹21.75 | ₹19.57 - ₹23.93 | -65.2% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹64.00 | ₹57.60 - ₹70.40 | +2.4% | ROE: 33.3%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹24.00 | ₹21.60 - ₹26.40 | -61.6% | EPS: ₹2.64, BVPS: ₹12.00 |
Want to compare with current market value? Check ASPIRA share price latest .
Valuation Comparison Chart
ASPIRA Intrinsic Value Analysis
What is the intrinsic value of ASPIRA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Aspira Pathlab (ASPIRA) is ₹24.00 (median value). With the current market price of ₹62.52, this represents a -61.6% variance from our estimated fair value.
The valuation range spans from ₹12.50 to ₹64.00, indicating ₹12.50 - ₹64.00.
Is ASPIRA undervalued or overvalued?
Based on our multi-method analysis, Aspira Pathlab (ASPIRA) appears to be trading above calculated value by approximately 61.6%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.67 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.50 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 33.3% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 16.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.33x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Aspira Pathlab
Additional stock information and data for ASPIRA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |